Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Minoru Tada
Based on 60 articles published since 2010
(Why 60 articles?)
||||

Between 2010 and 2020, Minoru Tada wrote the following 60 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3
51 Article Risk factors for pancreatitis following transpapillary self-expandable metal stent placement. 2012

Kawakubo, Kazumichi / Isayama, Hiroyuki / Nakai, Yousuke / Togawa, Osamu / Sasahira, Naoki / Kogure, Hirofumi / Sasaki, Takashi / Matsubara, Saburo / Yamamoto, Natsuyo / Hirano, Kenji / Tsujino, Takeshi / Toda, Nobuo / Tada, Minoru / Omata, Masao / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan. ·Surg Endosc · Pubmed #22011943.

ABSTRACT: BACKGROUND: Pancreatitis is one of complications after self-expandable metal stent (SEMS) placement. The purpose of this study was to evaluate risk factors for pancreatitis after endoscopic SEMS placement for malignant biliary obstruction (MBO). METHODS: We retrospectively reviewed 370 consecutive patients who underwent initial transpapillary SEMS placement for biliary decompression. The characteristics of inserted SEMSs were classified according to axial and radial force. RESULTS: Pancreatitis following SEMS insertion was observed in 22 patients (6%). All of them were mild according to consensus criteria. Univariate analysis indicated that injections of contrast into the pancreatic duct (frequency of pancreatitis, 10.3%), the placement of an SEMS with high axial force (8.3%), and nonpancreatic cancer (16.1%) significantly contributed to the development of pancreatitis, whereas female gender, a younger age, a covered SEMS, and a SEMS with high radial force or without a biliary sphincterotomy did not. In a multivariate risk model, SEMSs with high axial force (odds ratio [OR], 3.69; p = 0.022) and nonpancreatic cancer (OR, 5.52; p < 0.001) were significant risk factors for pancreatitis. CONCLUSIONS: SEMSs with high axial force and an etiology of MBO other than pancreatic cancer were strongly associated with a high incidence of pancreatitis following transpapillary SEMS placement in patients with distal MBO.

52 Article Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. 2011

Hamada, Tsuyoshi / Isayama, Hiroyuki / Nakai, Yousuke / Togawa, Osamu / Kogure, Hirofumi / Kawakubo, Kazumichi / Tsujino, Takeshi / Sasahira, Naoki / Hirano, Kenji / Yamamoto, Natsuyo / Arizumi, Toshihiko / Ito, Yukiko / Matsubara, Saburo / Sasaki, Takashi / Yagioka, Hiroshi / Yashima, Yoko / Mohri, Dai / Miyabayashi, Kohji / Mizuno, Suguru / Nagano, Rie / Takahara, Naminatsu / Toda, Nobuo / Tada, Minoru / Omata, Masao / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. ·Gastrointest Endosc · Pubmed #21794859.

ABSTRACT: BACKGROUND: Although the placement of self-expandable metal stents (SEMSs) has been widely accepted as palliation for distal malignant biliary obstruction, the risk factors for their early dysfunction remain unclear. OBJECTIVE: To identify risk factors for early (<3 months) SEMS dysfunction in unresectable pancreatic cancer. DESIGN: A multicenter retrospective study. SETTING: Five tertiary referral centers. PATIENTS: Patients were included who underwent first-time SEMS placement for distal malignant biliary obstruction caused by pancreatic cancer between April 1994 and August 2010. MAIN OUTCOME MEASUREMENTS: Rates and causes of early dysfunction were evaluated, and risk factors were analyzed. RESULTS: In all, 317 eligible patients were identified. Covered SEMSs were placed in 82% of patients. Duodenal invasion was observed endoscopically in 37%. The median time to dysfunction was 170 days. The rates of all and early SEMS dysfunction were 55% and 31%, respectively. The major causes of SEMS dysfunction were food impaction and nonocclusion cholangitis (21% each) in early dysfunction and sludge (29%) in nonearly dysfunction. The rate of early dysfunction was 42% with duodenal invasion and 24% without duodenal invasion (P = .001). Early dysfunction caused by food impaction was more frequent in patients with duodenal invasion (10% and 4%, P = .053). Duodenal invasion was a risk factor (odds ratio 2.35; 95% CI, 1.43-3.90; P = .001) in a multiple logistic regression model. LIMITATIONS: A retrospective design. CONCLUSIONS: Duodenal invasion is a risk factor for early SEMS dysfunction in patients with pancreatic cancer.

53 Article Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. 2011

Yamaguchi, Koji / Kanemitsu, Shuichi / Hatori, Takashi / Maguchi, Hiroyuki / Shimizu, Yasuhiro / Tada, Minoru / Nakagohri, Toshio / Hanada, Keiji / Osanai, Manabu / Noda, Yutaka / Nakaizumi, Akihiko / Furukawa, Toru / Ban, Shinichi / Nobukawa, Bunsei / Kato, Yo / Tanaka, Masao. ·Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. yamaguch@med.uoeh-u.ac.jp ·Pancreas · Pubmed #21499212.

ABSTRACT: OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) may derive from an intraductal papillary mucinous neoplasm (IPMN) of the pancreas or may develop in the pancreatic duct apart from IPMN. The purpose of this study was to define the clinicopathological features of these 2 entities and compare them with those of ordinary PDAC. METHODS: Of 765 patients who had surgical resection for IPMN, 122 were diagnosed as having PDAC derived from IPMN and 31 with PDAC concomitant with IPMN. In addition, 7605 patients with PDAC who were registered in the Japan Pancreas Society pancreatic cancer registry were compared with the above patients. RESULTS: Pancreatic ductal adenocarcinomas derived from IPMN and concomitant with IPMN were significantly smaller, less invasive, and less extensive than ordinary PDAC. The median survival of patients with the 2 conditions was significantly longer than for those with ordinary PDAC when compared overall or when limited to TS2 (2.0 cm < tumor size ≤ 4.0 cm) or TS3 (4.0 cm < tumor size ≤ 6.0 cm) cases. CONCLUSIONS: These findings suggest that PDAC concomitant with IPMN and PDAC derived from IPMN may have more favorable biological behaviors or be diagnosed earlier than ordinary PDAC.

54 Article Specific increase in serum autotaxin activity in patients with pancreatic cancer. 2011

Nakai, Yousuke / Ikeda, Hitoshi / Nakamura, Kazuhiro / Kume, Yukio / Fujishiro, Mitsuhiro / Sasahira, Naoki / Hirano, Kenji / Isayama, Hiroyuki / Tada, Minoru / Kawabe, Takao / Komatsu, Yutaka / Omata, Masao / Aoki, Junken / Koike, Kazuhiko / Yatomi, Yutaka. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ·Clin Biochem · Pubmed #21439952.

ABSTRACT: OBJECTIVES: To evaluate the potential clinical significance of serum autotaxin (ATX) level in patients with cancers of the digestive system. DESIGN AND METHODS: Serum ATX activity was measured as the lysophospholipase D activity in patients with cancer of the esophagus (n=8), stomach (n=18), colorectum (n=21), biliary tract (n=19), or pancreas (n=103) and in patients with benign pancreatic diseases (n=73). RESULTS: Among patients with various cancers of digestive system, increased serum ATX activity was predominantly observed among pancreatic cancer patients. Serum ATX activity was not increased in patients with chronic pancreatitis or pancreatic cysts. In the diagnosis of pancreatic cancer, the area under the receiver operating curve for serum ATX activity was 0.541 (95% CI, 0.435-0.648) for men and 0.772 (95% CI, 0.659-0.885) for women. No significant correlation was observed between serum ATX activity and CEA, CA19-9 or Dupan2 levels. CONCLUSION: Serum ATX activity may be useful for identifying pancreatic cancer when used together with other serum markers of pancreatic cancer.

55 Article Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. 2011

Kawakubo, Kazumichi / Tada, Minoru / Isayama, Hiroyuki / Sasahira, Naoki / Nakai, Yousuke / Yamamoto, Keisuke / Kogure, Hirofumi / Sasaki, Takashi / Hirano, Kenji / Ijichi, Hideaki / Tateishi, Keisuke / Yoshida, Haruhiko / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ·Gut · Pubmed #21398676.

ABSTRACT: BACKGROUND AND AIMS: Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been reported to be associated with extrapancreatic malignancies, but there have been no prospective studies evaluating the incidence of extrapancreatic cancers in patients with IPMNs. In this study, the frequency of patients with IPMNs developing extrapancreatic cancers during follow-up was examined. METHODS: 642 patients with IPMNs were prospectively followed up for 4.8 years on average. They underwent clinical examination at least twice a year. The incidence of the observed extrapancreatic malignancies was compared with the expected incidence of the age- and gender-matched general Japanese population based on the Vital Statistics of Japan. RESULTS: 40 extrapancreatic cancers developed in 39 patients during follow-up (1.3% per year). The most common malignancies were hepatocellular (n=7), colorectal (n=6), gastric (n=6), lung (n=5) and prostate cancers (n=4). The calculated standardised incidence rate of each of the malignancies was not significant, as follows: hepatocellular 2.17 (95% CI 0.87 to 4.47), colorectal 1.02 (0.37 to 2.21), gastric 0.76 (0.28 to 1.66), lung 0.75 (0.24 to 1.76) and prostate 1.00 (0.71 to 1.29). Pancreatic cancer was observed in 17 patients during the same period, with a standardised incidence rate of 10.7 (6.2 to 17.1). CONCLUSIONS: The incidence of extrapancreatic malignancies in patients with IPMNs was similar to that in the general population, whereas the incidence of pancreatic cancers was significantly high. Intraductal papillary mucinous neoplasms are not associated with systemic carcinogenesis except for pancreatic cancer.

56 Article Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. 2011

Yamao, Kenji / Yanagisawa, Akio / Takahashi, Kuniyuki / Kimura, Wataru / Doi, Ryuichiro / Fukushima, Noriyoshi / Ohike, Nobuyuki / Shimizu, Michio / Hatori, Takashi / Nobukawa, Bunsei / Hifumi, Michio / Kobayashi, Yuji / Tobita, Kosuke / Tanno, Satoshi / Sugiyama, Masanori / Miyasaka, Yoshihiro / Nakagohri, Toshio / Yamaguchi, Taketo / Hanada, Keiji / Abe, Hideki / Tada, Minoru / Fujita, Naotaka / Tanaka, Masao. ·Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan. kyamao@aichi-cc.jp ·Pancreas · Pubmed #20924309.

ABSTRACT: OBJECTIVE: The aim of this study was to elucidate the clinicopathological features and prognosis of mucinous cystic neoplasms (MCNs). MATERIALS AND METHODS: We performed a multi-institutional, retrospective study on a collected series of patients with MCN pathologically defined by ovarian-type stroma. Clinicopathological features and prognosis were investigated. RESULT: Mucinous cystic neoplasm was confirmed in 156 cases, including 129 adenomas (82.7%) and 21 noninvasive (13.4%) and 6 invasive carcinomas (3.9%). Patients with MCN were exclusively women (98.1%) with the mean age of 48.1 years. All but 1 MCN were in the pancreatic body/tail region with a mean size of 65.3 mm. Communication between the cyst and the pancreatic duct was found in 18.1%. The 3-, 5-, and 10-year survival rates were 97.6%, 96.6%, and 96.6%, respectively. A significant difference in the survival rates was observed between adenomas and carcinomas and between minimally invasive carcinomas and invasive carcinomas. Cyst diameter and presence of mural nodule were predictive of malignant MCN. CONCLUSIONS: Mucinous cystic neoplasm is a rare but distinctive pancreatic cystic neoplasm with a favorable overall prognosis. All MCNs should be resected to prevent malignant changes but can be observed for an appropriate time when the lesion is small without the presence of mural nodules.

57 Article Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. 2011

Nakai, Yousuke / Isayama, Hiroyuki / Sasaki, Takashi / Sasahira, Naoki / Tsujino, Takeshi / Kogure, Hirofumi / Yagioka, Hiroshi / Yashima, Yoko / Togawa, Osama / Arizumi, Toshihiko / Matsubara, Saburo / Hirano, Kenji / Tada, Minoru / Omata, Masao / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan. ·Crit Rev Oncol Hematol · Pubmed #20579902.

ABSTRACT: OBJECTIVE: To evaluate the impact of age and comorbidity on clinical outcomes in advanced pancreatic cancer. METHODS: Consecutive 237 patients with advanced pancreatic cancer were studied. Comorbidity was scored by Charlson comorbidity index (CCI). We compared the clinical outcomes by age or comorbidity. RESULTS: Sixty-nine patients were elderly (≥75 years), and CCI was 0 in 69 patients, 1 in 98, and ≥2 in 70. Gemcitabine-based chemotherapy was administered in 183 patients and was well tolerated in both elderly group and in those with comorbidities. In a multivariate analysis, CCI, not age, was prognostic in addition to PS, distant metastasis, chemotherapy and CA19-9: the hazard ratios of CCI 1 and ≥2 were 1.25 and 1.55, compared with CCI 0 (p=0.027). CONCLUSIONS: Gemcitabine-based chemotherapy can be an effective treatment, without significant toxicity, in elderly patients. Comorbidity, not age, was prognostic in patients with advanced pancreatic cancer.

58 Article Experiences of biliary interventions using short double-balloon enteroscopy in patients with Roux-en-Y anastomosis or hepaticojejunostomy. 2010

Tsujino, Takeshi / Yamada, Atsuo / Isayama, Hiroyuki / Kogure, Hirofumi / Sasahira, Naoki / Hirano, Kenji / Tada, Minoru / Kawabe, Takao / Omata, Masao. ·Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. tsujinot-int@h.u-tokyo.ac.jp ·Dig Endosc · Pubmed #20642611.

ABSTRACT: BACKGROUND: The efficacy of double-balloon enteroscopy (DBE) for biliary interventions has been shown in patients with surgical anatomy. However, the use of available endoscopic retrograde cholangiography accessories during this procedure is limited because of the length of the conventional instrument (200 cm). The aim of this study was to evaluate the feasibility of short DBE for managing biliary disorders in patients with a Roux-en-Y gastrectomy or hepaticojejunostomy (HJ). PATIENTS AND METHODS: Using a short enteroscope (152 cm) and commercially available endoscopic retrograde cholangiography accessories, biliary interventions were performed in six patients with Roux-en-Y reconstruction or HJ anastomosis. RESULTS: A total of 12 biliary interventions were performed; balloon dilations of the HJ anastomosis or intrahepatic ducts (four patients), nasobiliary drainages (three patients), bile duct stone removal after endoscopic papillary large balloon dilation with or without small sphincterotomy (two patients), and a biliary stent placement (one patient). One patient showed retroperitoneal air following endoscopic papillary large balloon dilation, but recovered conservatively. CONCLUSIONS: Biliary interventions via DBE using a short enteroscope are feasible in patients with surgical anatomy.

59 Article Impact of S-1 on the survival of patients with advanced pancreatic cancer. 2010

Nakai, Yousuke / Isayama, Hiroyuki / Sasaki, Takashi / Sasahira, Naoki / Ito, Yukiko / Kogure, Hirofumi / Togawa, Osamu / Matsubara, Saburo / Arizumi, Toshihiko / Yagioka, Hiroshi / Yashima, Yoko / Kawakubo, Kazumichi / Mizuno, Suguru / Yamamoto, Keisuke / Hirano, Kenji / Tsujino, Takeshi / Ijichi, Hideaki / Tateishi, Keisuke / Toda, Nobuo / Tada, Minoru / Omata, Masao / Koike, Kazuhiko. ·Department of Gastroenterology, University of Tokyo, Bunkyo-ku, Tokyo, Japan. ·Pancreas · Pubmed #20467352.

ABSTRACT: OBJECTIVE: The aim of this study was to investigate the effect of S-1 on the prognosis of advanced pancreatic cancer. METHODS: In total, 112 patients with pancreatic cancer who received chemotherapy between April 2001 and April 2007 were divided into 2 groups: PreS-1 (53 patients who started chemotherapy before January 2005) and PostS-1 (59 patients who started chemotherapy after February 2005, the time of S-1 introduction). Patient characteristics and clinical outcomes were compared, and prognostic factors were analyzed. RESULTS: Patient characteristics did not significantly differ between the 2 groups. S-1 was administered as a second-line monotherapy in 5.7% of the PreS-1 group and combined with gemcitabine as a first-line therapy in 27.1% or as second-line monotherapy in 23.7% in the PostS-1 group. Both progression-free survival and overall survival improved after introduction of S-1 (median progression-free survival, 4.4 and 5.3 months; P = 0.043; median overall survival, 9.5 and 13.1 months; P = 0.048 in PreS-1 and PostS-1 groups, respectively). Multivariate analysis revealed that the PostS-1 group (hazards ratio, 0.52; P = 0.003), performance status, and carcinoembryonic antigen were significant prognostic factors for survival. CONCLUSIONS: Introduction of S-1 may improve the prognosis of Japanese patients with advanced pancreatic cancer.

60 Minor Intraductal papillary mucinous neoplasm was associated with pancreatic carcinogenesis, but not with systemic carcinogenesis. 2012

Kawakubo, Kazumichi / Tada, Minoru / Koike, Kazuhiko. · ·Surgery · Pubmed #22575879.

ABSTRACT: -- No abstract --

Back